Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma

BACKGROUND/AIMS: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP) has improved survival in patients with diffuse large B-cell lymphoma (DLBCL) and weakened the prognostic power of the international prognostic index (IPI). We evaluated the efficacy of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Changhoon, Kim, Shin, Sohn, Byeong Seok, Kim, Jeong-Eun, Yoon, Dok Hyun, Huh, Jooryung, Lee, Dae Ho, Kim, Sang-We, Lee, Jung-Shin, Suh, Cheolwon
Formato: Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2932944/
https://www.ncbi.nlm.nih.gov/pubmed/20830228
http://dx.doi.org/10.3904/kjim.2010.25.3.301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2932944/
https://www.ncbi.nlm.nih.gov/pubmed/20830228
http://dx.doi.org/10.3904/kjim.2010.25.3.301

Ejemplares similares